# Research Brief: Healthcare AI Review Queue

## Objective

Prepare a source-bounded report arguing that healthcare AI should begin a new review year with a triage queue rather than a blank slate. The report should help downstream drafting turn unresolved governance work into visible review actions without inventing local facts or overclaiming what a queue proves.

## Recommended Title Direction

- Preferred: `Healthcare AI Starts the Year With a Review Queue`
- Acceptable alternate: `The First AI Governance Job Is Sorting the Queue`
- Avoid repeating recent title frames centered on carry-forward files, transparency, permission lines, renewal, fallback, near misses, or generic monitoring.

## Reader and Use Case

Primary readers are healthcare leaders, clinical informatics teams, operational owners, safety leaders, privacy/security partners, and governance groups. The piece should frame the first review cycle as an operating problem: what needs review first, why it is in queue, who owns the next action, and what decision closes, narrows, pauses, retires, or escalates the item.

## Core Thesis

The staged source boundary supports a first-cycle review-queue argument:

1. The prior year can end with unresolved AI governance questions still visible.
2. The first review cycle should convert that handoff into a queue that routes work.
3. The queue is an operating surface, not a proof artifact.
4. Unknown or stale fields should stay visible rather than being mistaken for clearance.

## Narrative Spine

Use this flow for both locales:

1. Open with the year-boundary problem: AI governance work continues even when the calendar resets.
2. Explain the queue as a routing surface for owners, triggers, evidence needs, monitoring review, validation review, fallback review, retirement review, and escalation.
3. Show what makes a queue actionable:
   - workflow or AI-enabled function;
   - owner or owner group;
   - trigger;
   - current status;
   - last review date or review thread;
   - next action;
   - evidence, monitoring, source-attribute, validation, fallback, and incident-related gaps;
   - decision needed and escalation route.
4. Close on prioritization and decision rights: the queue exists to sort review work, not to certify safety, compliance, maturity, or effectiveness.

## High-Value Points To Include

- Trigger examples: unresolved carry-forward item, new or changed use, expanded user group or setting, changed output or downstream action, source-attribute update, monitoring exception, near miss, incident, owner change, fallback gap, pending validation, or retirement question.
- Safe status examples: `intake-needed`, `owner-confirm-needed`, `evidence-needed`, `monitoring-review-needed`, `validation-needed`, `fallback-review-needed`, `decision-needed`, `paused`, `retired`, and `closed`.
- Evidence posture: separate evidence that exists from evidence that is missing, stale, vendor-only, unreviewed, or not locally validated.
- Monitoring posture: capture what signal exists, who reviews it, when it was last reviewed, and whether thresholds or escalation paths are defined.
- Fallback posture: preserve what happens if the AI-enabled function is unavailable, who switches to fallback, and whether the fallback path was reviewed or tested.
- Decision posture: tie each open item to a concrete action such as request evidence, confirm owner, review monitoring, validate locally, clarify use boundary, narrow use, pause use, retire/archive, or escalate.

## Required Evidence Posture

Treat the report as source-bounded governance guidance, not as proof about any real hospital, vendor, product, regulator, or local queue. The downstream report should preserve locale-specific `EVIDENCE_GRADE_WARN` comments near the opening and again mid-report. It should also include a short `Selected Source Basis` section in both `en` and `zh`.

## Boundaries and Red Lines

- Do not claim any named organization has or lacks this queue.
- Do not present the queue as legal advice, a compliance calendar, or proof of safe or effective AI use.
- Do not invent owners, review dates, incident counts, validation results, audit findings, risk tiers, or committee structures.
- Do not imply that lower-priority items are safe or that higher-priority items are unsafe.
- Do not treat bounded FDA device context as the whole healthcare AI landscape.
- Do not use runtime metadata, transcripts, run-state files, or repo-internal artifacts as reader-facing evidence.

## Implementation Notes For Drafting

- Keep the H1 free of the week key.
- Keep the frame centered on review-queue triage and first-cycle sorting.
- Preserve explicit evidence limits in both locales, with Chinese warning prose translated rather than copied in English.
- Use a short `Selected Source Basis` section naming the staged basis: NIST AI RMF, ONC SAFER system management and contingency planning, ONC decision-support intervention material, WHO governance/ethics, AMA augmented intelligence guidance, Joint Commission/CHAI responsible AI adoption guidance, and bounded FDA device-context material.

## Known Source Gaps

- No local review queue, owner map, calendar, audit log, utilization data, incident log, validation result, or measured outcome is available in the staged material.
- The staged files name external source families but do not provide fetched primary-text excerpts in this run directory.
- Any downstream report should state these gaps plainly rather than filling them with examples or inferred local practice.
